Vol. 298, Issue 2, 477-484, August 2001

Tumor Growth Inhibition in Vivo and G₂/M Cell Cycle Arrest Induced by Antisense Oligodeoxynucleotide Targeting Thymidylate Synthase

Randal W. Berg, Melanie Werner, Peter J. Ferguson, Carl Postenka, Mark Vincent , D. James Koropatnick and Elke Behrend

Cancer Research Laboratories, The London Regional Cancer Centre, London, Ontario, Canada (R.W.B., M.W., P.J.F., C.P., E.B., M.V., D.J.K.); and Departments of Oncology (M.V., D.J.K.), Microbiology and Immunology, Pathology, and Pharmacology and Toxicology (D.J.K.), The University of Western Ontario, London, Ontario, Canada

Chemotherapeutic agents targeting thymidylate synthase (TS) are effective against human tumors. Efficacy is limited by drug resistance, often mediated by TS overexpression. Treatment of HeLa cells in vitro with an antisense oligodeoxynucleotide (ODN 83) targeting human TS mRNA reduces TS mRNA and protein levels, inhibits cell proliferation, and sensitizes cells to TS-targeting drugs (Ferguson et al., 1999). The present study investigates the mechanism by which ODN 83 inhibits cell proliferation and examines its antitumor efficacy in vivo. ODN 83 treatment did not induce apoptosis in HeLa cells in vitro but caused accumulation of cells at G₂/M. In contrast, TS-targeting chemotherapeutics arrest at G₁ or S. Antisense down-regulation reduced TS mRNA levels in human colon cancer (HT29) cells by 40% in vitro, resulted in G₂/M arrest, and reduced proliferation without enhanced cell death. Growth of HT29 tumors in immunocompromised mice was significantly inhibited when antisense ODN 83 treatment began promptly after tumor implantation and was accompanied by a 40% reduction in TS protein levels. Growth of tumors allowed to reach 400 mm³ prior to ODN administration was unaffected by antisense ODN 83. Radiolabeled ODNs were localized to the tumor periphery but evenly distributed in normal tissue. Thus, down-regulation of TS mRNA and protein by antisense ODN treatment exerts a novel G₂/M cell cycle block without increasing cell death and inhibits HT29 tumor cell growth in vivo. Antisense ODN 83 may be an effective therapy for colon carcinoma, alone or in combination with TS-targeting cytotoxic drugs.